The drug inhibits RNA polymerase II-dependent transcription of mRNA by blocking the phosphorylation of its COOH-terminal domain, and thereby prevents global transcription including HIF-1α [35,36,37], leading to anti-tumor effects, confirmed in a clinical study [38,39]. Here, HIF1A is linked to neoplasm.